PREGNANCY AND AUTOIMMUNE DISORDERS: IMPLICATIONS FOR MATERNAL AND FETAL HEALTH

Abstract

Autoimmune disorders represent a heterogeneous group of chronic conditions characterized by dysregulated immune responses directed against self-antigens. These diseases frequently affect women of reproductive age, making pregnancy management clinically significant. Gestation induces complex immunological, hormonal, and metabolic adaptations that may alter disease activity, influence obstetric outcomes, and affect fetal development. Certain disorders improve in pregnancy; others are quiescent or exaggerated and confer an increased risk of complications including preeclampsia, preterm labour, fetal growth restriction and neonatal immune sequelae [4, 5]. Timely assessment and stratification of risks, multidisciplinary follow up and differentiation in treatment planning based on maternal stability and fetal safety represent crucial steps. In this article, immunopathological mechanisms, clinical features, management principles and outcomes related to autoimmune diseases in pregnant patients are reviewed with a focus on evidence-based approaches to minimize morbidity and mortality. Pregnancy in the context of autoimmune disorders is a clinically challenging dilemma because these patient groups experience unique immunological, hormonal and vascular adaptations which affect disease course and obstetric outcomes. Autoimmune disorders like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), antiphospholipid syndrome, autoimmune thyroid disease, and multiple sclerosis can show a variable response to pregnancy with respect to remission, exacerbation, or unpredictable fluctuation during pregnancy and in the postpartum period. Maternal immune tolerance of the semi-allogeneic fetus necessitates precise immunomodulation that can affect autoantibody production and inflammatory pathways. Such changes may alter placental function leading to miscarriage, preeclampsia, fetal growth restriction, preterm birth and neonatal complications. Maternal and neonatal prognosis depends on early diagnosis, preconception counseling, multidisciplinary monitoring, and individualized pharmacotherapy. In this article, we will overview immunopathophysiological viral mechanisms, clinical features, diagnostic protocols and recent management strategies to ensure the best possible clinical outcomes for the mother and child. Type autoimmune diseases predominantly first run into women during their reproductive years and pose considerable clinical challenges when they overlap with pregnancy. Mechanistic processes that underlay these physiological adaptations contributing to fetal tolerance include modulation of innate and adaptive immunity, endocrine adaptations, and vascular remodeling. Such modifications may change the trajectory of disease by either dampening levels of inflammatory activity or precipitating exacerbations in accordance with the immunopathology that underpins the chronic lung disease process. Dysregulated immune mechanisms, including maternal autoantibodies, systemic inflammation, and endothelial dysfunction, can disrupt placentation and fetal growth. Pregnancy syndrome with a high level of disease control leads to outcomes such as hypertensive disorders of pregnancy and preterm birth, intrauterine growth restriction and transitioning neonatal immune changes with high frequency. Nevertheless, well planned conception, suitable medical interventions, and organized follow-up dramatically enhance outcomes. Modern-day validation reinforces the continued necessity of immunologic quietude, as well as avoiding exacerbations, and safe therapeutic exposure in both pregnancy and the postpartum period.